US FDA sets denosumab panel review for August
This article was originally published in Scrip
The US FDA's reproductive health drugs advisory panel will review Amgen's fully human monoclonal antibody denosumab (proposed trade name Prolia) on August 13th for osteoporosis and bone loss resulting from cancer treatment.
You may also be interested in...
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.
CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.